Carla Coffin

cscoffin@ucalgary.ca


In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Pam Ford

Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody

Simmone D'Souza

HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis

David Wong

Biologiste Médical

Ronald Simeon

Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis

Richard Morrow

Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review

Moses Donkor

Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections

Desmond Osei

EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Yashasavi Sachar

HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING

Yashasavi Sachar

Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD

Dong Hyun (Danny) Kim

Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis

Thomas Michalak

Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Alexa Thompson

Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience

Sébastien Poulin

Functional cure of chronic HBV infection

David Wong

Using discrete field documentation in Epic EMR for clinical research of hepatitis B

David Wong

A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex

Archee Panwar

Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection

Layla Al-Yasiri

Chronic HBV infection in Toronto, Canada: Tale of two clinics

David Wong

Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.

Nana Frimpong

Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)

Justine Beghin

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study

Golasa Samadi Kochaksaraei

Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study

Golasa Samadi Kochaksaraei

Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening

Carla Osiowy

IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa

Loghman Salimzadeh

Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba

Carla Osiowy

Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Valeriya Zaborska

PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model

Hoda Poorbagher

G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections

Jessica Skoreyko

Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors

Kuldeep Kaur

Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort

Jean Makuza

Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time

Curtis Cooper

Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia

Abdulrhman Alamr

Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto

David Wong

Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges

Colina Yim

Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin

Kira Sviderskaia

Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy

Frank Hyun

Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement

Emma Kasinyabo

Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection

Muhammad Atif Zahoor

Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex

Mohaddeseh Pakzamir

Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots

Michelle Tang

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Curtis Cooper

Under Review

Profile Summary

Submission ID PROR1YSG9QN
Name Curtis Cooper
Call Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission
Email Address ccooper@toh.ca
Title Professor of Medicine and Scientist
Organization University of Ottawa and The Ottawa Hospital Research Institute

Session

Title Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time
Description

Background- It is uncertain if HBV GT influence viral and/or liver markers over time or impact nucleos(t)ide response.
Purpose- We utilized Ottawa Hospital Viral Hepatitis Program cohort data to retrospectively evaluate HBV GT on viral and liver measures over time.
Methods- Analysis were stratified by antiviral treatment status during follow-up. HBV DNA, ALT/AST levels and transient elastography scores (E, CAP) were modelled using mixed effects linear regression with HBV GT and time interaction terms.
Results- 393 with GT A-E were included. Mean age was 44.4 years and 56% were male. Asian (50.5%), Black (29.1%) and White (6.4%) patients were well represented. By multivariate analysis, the trajectories of all viral and liver measures assessed did not vary by genotype. In those initiating nucleos(t)ide analogue therapy, the crude median time to HBV DNA suppression was 181 days and ALT/AST normalization was 91 days which did not differ by GT.
Discussion- We found no evidence that the trajectories of the commonly measured viral and liver measures vary over time by HBV GT.
Track Hepatitis B (including HDV, HCV, HIV Co-infections) - Clinical Science
Formats
Audiences

Co-Presenters

Name Alexa Keeshan
Organization OHRI
State/Province Ontario
City Ottawa
Email akeeshan@ohri.ca
Website N/A
Speaker Role
Name Alicia Vachon
Organization U Ottawa
State/Province Ontario
City Ottawa
Email avachon@ohri.ca
Website N/A
Speaker Role
Name Carolina Fernandes da Silva
Organization U Ottawa
State/Province Ontario
City Toronto
Email carolina.fernandesdasilva@mail.utoronto.ca
Website N/A
Speaker Role

Submit Review



Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?